Clinical Trial Update: The Effects of Nanocurcumin on Treg Cells and Th17 Cells Responses in Ankylosing Spondylitis Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating the effects of nanocurcumin on regulatory T and Th17 cell responses in patients with Ankylosing Spondylitis; study complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Nanocurcumin (curcumin nanoparticle formulation)

Snippet

Sponsor: Tabriz University of Medical Sciences | Conditions: Ankylosing Spondylitis | Phase 2 | Status: COMPLETED